Pharmacy Urges US FDA To Disallow Levels Of DMF Solvent It Found In Valsartan
Executive Summary
The saga of tainted valsartan has taken another turn with an online pharmacy that tests its medications before dispensing them finding yet another probable carcinogen in lots of the blood pressure medication from multiple manufacturers. The pharmacy filed a citizen petition asking the US FDA to tighten its globally harmonized limit for the residual solvent.
You may also be interested in...
Pharmacy Calls For The FDA To Require Independent Third-Party Testing
An online pharmacy that tests medications before dispensing them advocated for regulations requiring independent testing and verification of the chemical content of pharmaceuticals; it also alleged that the US FDA’s testing method for evaluating the carcinogenic risk of metformin needs refinement.
Cleveland Clinic Drug Quality Dashboard Helps Guide Product Choices
After realizing some generics don’t work, academic medical center screens quality by manufacturer. Other providers protest: It’s not our job.
FDA And EMA Evaluate Claims As Nitrosamine Worries Turn To Zantac
Pharmacy petitions for recalls after finding ‘inherent instability’ in antacid that could pose carcinogenic risk.